Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Int J Mol Sci 2024;25:11363
The Clinical Trial Journey: From Promise to Disappointment Phase 1: Safety Confirmed Athira Pharma developed fosgonimeton, an intravenous formulation of Dihexa, for clinical trials
A vial isnt just 5mg or 10mg in isolation that mass has to be matched against the intended use volume, and the same mass can support meaningfully different concentrations depending on how much diluent is introduced
When her GP saw the results, she was shocked and told my daughter she had never seen a result for B12 like that
In this context, research strategies aimed at the selective inhibition of FOXO proteins including the use of peptide analogs such as FOXO4-DRI represent a promising approach for investigating the modulation of metabolic pathways, with potential relevance to diabetes-related complications
